Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis.

Madeline Dahut,Kristen Fousek,Lucas A Horn,Shantel Angstadt,Haiyan Qin,Duane H Hamilton,Jeffrey Schlom,Claudia Palena

Journal for immunotherapy of cancer（2023）

引用 0|浏览1

暂无评分

摘要

NK cells are emerging as a promising therapeutic approach in prostate cancer. Modifying tumor plasticity via blockade of estrogen receptor with fulvestrant may offer an opportunity for immune intervention via NK cell-based approaches in enzalutamide-resistant CRPC.

查看译文

关键词

Immune Evation, Prostatic Neoplasms, Killer Cells, Natural

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要